激素治疗对DIEP重建安全性的匹配队列分析
结果显示HT组总体并发症(28% vs 15%,P=0.04)和静脉血栓栓塞(7.0% vs 0%,P=0.03)显著更高,术中血栓及皮瓣完全丢失无差异,提示术前应停用激素治疗。
要点
- 术前HT与DIEP重建后总体并发症风险升高相关(28% vs 15%,P=0.04)。
- HT组静脉血栓栓塞发生率显著高于NH组(7.0% vs 0%,P=0.03)。
- 术中血栓及术后皮瓣完全丢失在两组间无显著差异。
核心结论
- 术前激素治疗与DIEP重建后总体并发症及静脉血栓栓塞风险显著增加相关,建议术前停用激素治疗。
主要发现
- HT组总体并发症发生率为28%,NH组为15%,差异有统计学意义(P=0.04)。
- HT组静脉血栓栓塞发生率为7.0%,NH组为0%,差异有统计学意义(P=0.03)。
- 两组术中血栓发生率和术后皮瓣完全丢失率相似。
关键数值与推荐
- 匹配变量包括体重指数、吸烟、重建时机、乳房切除指征、放疗史和糖尿病史。
- 总体并发症:HT组28% vs NH组15%,P=0.04。
- 静脉血栓栓塞:HT组7.0% vs NH组0%,P=0.03。
临床怎么用
- 对计划行DIEP重建的乳腺癌患者,术前应评估激素治疗状态并考虑暂停。
- 术后需警惕静脉血栓栓塞风险,尤其是有激素治疗史的患者。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 未报告激素治疗的具体药物、剂量或停药时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormonal therapy (HT) has become a mainstay in the treatment of receptor-positive breast cancers. There have been conflicting reports regarding the effects of HT after autologous breast reconstruction (ABR), with some reports suggesting that patients on HT have a higher risk of complications and flap failure, whereas other studies bolster the perioperative safety of HT. Here, the authors present a matched cohort analysis to determine whether HT affects outcomes following ABR. METHODS: A retrospective review was conducted on patients undergoing ABR between 2016 and 2020. Patients were split into 2 cohorts: those on HT and those not on hormonal therapy (NH), based on a 1:1 propensity matching using variables known to be risk factors for complications after deep inferior epigastric perforator flap reconstruction, including body mass index, smoking, timing of reconstruction, mastectomy indication, and history of radiation and diabetes. RESULTS: Eighty-five patients were matched into the HT and NH cohorts. Overall, patients in the HT cohort were significantly more likely to develop a complication (HT: 28% versus NH: 15%; P = 0.04). The incidence of intraoperative thrombosis was similar between the cohorts, as was the incidence of postoperative total flap loss. Patients in the HT cohort had a significantly increased risk of venous thromboembolism than those in the NH cohort (HT: 7.0% versus NH: 0%; P = 0.03). CONCLUSIONS: This is the first study examining the effects of preoperative HT on ABR, with matched cohorts to control for comorbidities. Patients in the HT cohort had a significantly higher risk of complications and venous thromboembolic events, suggesting that they should discontinue HT before surgery.
引用
- Patel V, Quick J, Wu S, et al. Safety of Hormonal Therapy Prior to DIEP Reconstruction: A Matched Cohort Analysis. Plast Reconstr Surg. 2025. PMID: 41428960. doi:10.1097/PRS.0000000000012741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。